A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms START 2
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 Planned End Date changed from 31 Mar 2021 to 31 Dec 2022.
- 06 Apr 2013 New trial record